Unichem Laboratories Ltd

₹ 349 -1.47%

29 May - close price

unichemlabs.com BSE: 506690 NSE: UNICHEMLAB

About

Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.^[1]

Key Points

Therapeutic Areas
The company manufactures and markets APIs and pharmaceutical formulations as branded & non-branded generics. The company’s products cater to diverse therapeutic areas such as cardiology, gas, diabetology, gastroenterology psychiatry, neurology, antibacterial, anti-infective, and pain management. ^[1]

Website BSE NSE

Market Cap ₹ 2,460 Cr.
Current Price ₹ 349
High / Low ₹ 667 / 278
Stock P/E
Book Value ₹ 373
Dividend Yield 0.00 %
ROCE -0.22 %
ROE -0.69 %
Face Value ₹ 2.00

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.
Stock is trading at 0.94 times its book value

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has low interest coverage ratio.
The company has delivered a poor sales growth of 4.67% over past five years.
Company has a low return on equity of 1.44% over last 3 years.
Earnings include an other income of Rs.290 Cr.
Company has high debtors of 151 days.
Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	310	347	334	362	399	390	437	448	461	384	357	315	356
	319	338	341	343	369	350	372	374	386	359	349	314	344
Operating Profit	-9	8	-7	19	31	40	64	74	75	26	8	1	12
OPM %	-3%	2%	-2%	5%	8%	10%	15%	17%	16%	7%	2%	0%	4%
	-104	6	8	78	-119	9	7	19	10	4	-12	291	10
Interest	3	2	4	2	2	1	2	3	2	2	4	2	4
Depreciation	28	27	27	26	25	26	26	28	27	30	30	30	29
Profit before tax	-144	-16	-31	69	-115	21	43	62	56	-2	-38	260	-11
Tax %	0%	0%	0%	0%	0%	0%	0%	24%	9%	-1%	6%	17%	44%
	-144	-16	-31	69	-115	21	43	47	51	-2	-40	216	-15
EPS in Rs	-20.43	-2.23	-4.38	9.84	-16.33	3.05	6.16	6.66	7.27	-0.26	-5.67	30.69	-2.19
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,091	1,221	576	666	968	904	1,124	943	1,072	1,442	1,736	1,412
	989	1,078	813	798	1,019	994	1,028	986	1,165	1,391	1,482	1,362
Operating Profit	102	142	-237	-132	-52	-89	95	-43	-93	51	254	50
OPM %	9%	12%	-41%	-20%	-5%	-10%	8%	-5%	-9%	4%	15%	4%
	20	19	366	2,737	94	98	47	42	-71	-27	45	290
Interest	2	2	2	3	1	1	1	2	9	10	8	12
Depreciation	38	35	39	45	62	71	76	83	106	105	108	119
Profit before tax	82	124	87	2,556	-20	-64	66	-87	-279	-92	183	209
Tax %	21%	19%	-19%	-0%	-144%	-12%	18%	-36%	7%	0%	11%	24%
	64	100	104	2,557	9	-56	54	-55	-300	-92	163	159
EPS in Rs	7.09	11.06	11.43	363.48	1.25	-8.00	7.68	-7.87	-42.57	-13.09	23.15	22.57
Dividend Payout %	28%	18%	26%	1%	320%	-50%	52%	-51%	-9%	0%	0%	0%

Compounded Sales Growth
10 Years:	1%
5 Years:	5%
3 Years:	10%
TTM:	-19%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	24%
TTM:	-111%

Stock Price CAGR
10 Years:	3%
5 Years:	1%
3 Years:	-2%
1 Year:	-42%

Return on Equity
10 Years:	10%
5 Years:	-1%
3 Years:	1%
Last Year:	-1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	18	18	18	14	14	14	14	14	14	14	14	14
Reserves	929	1,009	1,113	2,748	2,718	2,633	2,683	2,658	2,370	2,281	2,446	2,613
	0	8	1	0	0	17	1	132	108	70	123	64
	274	306	371	346	298	361	420	318	394	477	527	401
Total Liabilities	1,222	1,342	1,503	3,108	3,030	3,025	3,119	3,122	2,886	2,842	3,109	3,092
	396	381	468	555	789	829	850	963	1,236	1,165	1,275	1,189
CWIP	119	233	247	236	90	331	568	494	148	122	31	100
Investments	153	111	89	979	1,042	668	520	390	41	44	46	47
	555	617	698	1,338	1,109	1,197	1,181	1,275	1,462	1,510	1,758	1,755
Total Assets	1,222	1,342	1,503	3,108	3,030	3,025	3,119	3,122	2,886	2,842	3,109	3,092

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	88	117	141	-66	-251	-42	-33	-158	-117	-42	72	53
	-62	-87	-132	1,648	-323	-36	-73	104	241	60	-133	208
	-47	-39	-9	-930	-45	-21	-45	96	-62	-48	-5	-71
Net Cash Flow	-21	-9	-0	653	-619	-98	-150	42	62	-30	-65	190
Free Cash Flow	12	-17	-2	-219	-440	-419	-318	-285	-153	-53	-38	216
CFO/OP	104%	104%	-71%	52%	472%	50%	-34%	375%	126%	-81%	29%	104%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	69	79	188	127	125	130	117	147	161	141	157	151
Inventory Days	159	162	371	216	242	301	326	438	335	264	267	325
Days Payable	122	153	334	220	170	199	159	150	170	132	120	124
Cash Conversion Cycle	106	88	225	123	197	233	284	436	325	274	305	352
Working Capital Days	95	98	233	190	222	215	208	271	254	199	202	248
ROCE %	9%	13%	-8%	132%	-0%	-2%	2%	-3%	-6%	-1%	7%	-0%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Abbreviated New Drug Applications (ANDA) - Cumulative Filings
Number

xx	xx	xx		xx	xx	xx	xx	xx	xx	xx
x,xxx	x,xxx	x,xxx	x,xxx		x,xxx	x,xxx	x,xxx		x,xxx
		x	x		x	x		x	x	x
xx	xx	xx				xx		xx	xx	xx
			x		xx	x	x	x	x	x
xx	xx	xx	xx	xx						xx
					x	x	x	x	x	x
xx	xx	xx								xx
					x.xx				x.xx	xx.xx
xx	xx
							xx.xx	xx.xx	x.xx	x.xx

Please log in to see hidden values.

Total Employee Strength
Number

ANDA Filings during the Year
Number

Drug Master Files (DMF) - Cumulative US Filings
Number

Products Launched in US Generic Market during the Year
Number

ANDA Approvals - Cumulative
Number

ANDA Approvals during the Year
Number

CEP (European DMF) - Cumulative Filings
Number

Formulation Output Volume (Tablets/Capsules)
Billion Units

Chronic Therapy Contribution to Domestic Formulation Revenue
Percentage

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	50.94%	70.21%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%	70.22%
	1.62%	0.83%	0.84%	0.90%	0.89%	0.94%	1.05%	0.98%	0.98%	0.99%	0.99%	1.00%
	9.65%	10.00%	10.46%	11.26%	11.57%	11.65%	11.63%	11.32%	10.92%	10.74%	10.73%	10.63%
	37.80%	18.95%	18.47%	17.63%	17.32%	17.17%	17.11%	17.47%	17.88%	18.04%	18.05%	18.14%
No. of Shareholders	26,642	21,584	20,877	21,171	20,621	20,374	21,472	21,621	23,010	23,577	23,267	23,386

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	50.08%	50.67%	50.64%	50.74%	50.93%	50.93%	50.94%	70.22%	70.22%	70.22%
	4.04%	5.34%	2.13%	1.76%	1.50%	1.47%	1.70%	0.90%	0.98%	1.00%
	12.62%	5.93%	7.28%	9.46%	8.94%	9.59%	8.15%	11.26%	11.32%	10.63%
	33.26%	38.06%	39.95%	38.04%	38.62%	38.01%	39.21%	17.63%	17.47%	18.14%
No. of Shareholders	25,539	45,695	39,785	36,355	33,734	33,557	29,418	21,171	21,621	23,386

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Jun 2017

Transcript

AI Summary
PPT
Feb 2017
Transcript PPT
Nov 2016
Transcript PPT
Aug 2016
Transcript PPT
Jun 2016
Transcript PPT
Feb 2016
Transcript PPT